THERAPEUTIC USES OF EMPAGLIFLOZIN
CY1125680T1Undetermined Publication Date: 2026-04-17BOEHRINGER INGELHEIM INT GMBH
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- CY20221100763T
- Authority / Receiving Office
- CY · CY
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2014-02-20
- Filing Date
- 2022-12-05
- Publication Date
- 2026-04-17
- Estimated Expiration
- 2042-12-05
Abstract
The present invention relates to certain SGLT-2 inhibitors for the treatment and / or prevention of oxidative stress, for example in patients with type 1 or type 2 diabetes, as well as the use of such SGLT-2 inhibitors in the treatment and / or prevention of cardiovascular disease in patients, for example in patients with type 1 or type 2 diabetes. The present invention also relates to certain SGLT-2 inhibitors for the treatment and / or prevention of a metabolic disorder and for preventing, reducing the risk of or delaying the occurrence of a cardiovascular event in patients with type 1 or type 2 diabetes.
Need to check novelty before this filing date? Find Prior Art